AcuraStem is a California-based biotechnology company employing cutting-edge technology in its efforts to find treatments and cures for neurodegenerative diseases (NDDs). AcuraStem’s team of PhDs, professors, tech entrepreneurs, and successful drug company veterans are employing the latest scientific breakthroughs to address the most challenging, but we believe tractable, health problems of our time, including amyotrophic lateral sclerosis (ALS).

Our best-in-class technology platform consists of complex cellular models from ALS patient cells and sophisticated assays which permit AcuraStem’s scientists to model patient tissues in the laboratory. Using this ground-breaking technology, we can screen small molecule or gene targeting libraries to discover the most efficacious therapeutic opportunities.

AcuraStem’s iNeuroRx® platform is a breakthrough disease modeling platform, leveraging neurons derived from patients and advanced machine learning to discover therapeutic opportunities that rescue healthy motor neurons in those affected by neurodegenerative diseases, like ALS and FTD (frontotemporal dementia). AcuraStem has found unique therapeutic targets that work broadly for many types of ALS patients. Therefore, AcuraStem is developing PIKFYVE target therapeutics for ALS and FTD. Its most advanced drug candidate, AS-202, is in IND-enabling toxicity studies.


AcuraStem's founders wanted a name that would communicate the team's vision for utilizing stem cell models in a novel way. The name represents a more accurate way to predict disease progression and a patient's response to therapy. Initially the team focused on the name "AcurateStem," but subsequently changed it to “AcuraStem” with a capital S emphasizing the use of stem cells. Another meaning embedded in AcuraStem’s name is cure. We aim to accurately diagnose, and potentially cure, neurodegenerative diseases with stem cells. The name "AcuraStem," conveys the unwavering focus of the entire company in one simple, unique word, reflecting the very nature of our endeavor to advance cures in the near future for diseases where cures seem far from reach.  



Sam Alworth

Mr. Samuel V. Alworth, MS, MBA, Chief Executive Officer and Co-Founder, has nearly 20 years’ experience in the life sciences covering research, drug development and business development. Since co-founding AcuraStem, he has been actively involved in advancing drug candidates for ALS / FTD. With a background in machine learning and image recognition, Sam has led the implementation of new informatics pipelines at AcuraStem, incorporating both innovative machine learning and traditional image processing algorithms into a Unix based cloud-distributable pipeline leveraging best-in-class open source algorithms for the iNeuroRx® platform. Prior to co-founding AcuraStem, Mr. Alworth was VP of Sales & Marketing at DRVision Technologies LLC (Bellevue, WA), where he led the development of an artificial intelligence enabled software for automated microscopy (SVCell, now Aivia). Sam has several U.S. patents and scientific journal publications. He also speaks Chinese.

Paul August

Dr. Paul August, PhD, Co-Founder, has held key scientific and leadership roles for over 20 years with the global pharmaceutical company Sanofi, and presently as Head of Rare Genetic Disease Biology at Agios Pharmaceuticals. He has extensive drug discovery and development experience, and particularly in neuromuscular disease. Dr. August’s research has been particularly focused on developing disease-relevant, human-stem-cell-derived models.

Kirsten Bjergarde

Kirsten Bjergarde is current Head of Chemistry at AcuraStem and CEO of Corizona, LLC. She has over 20 years experience in the drug discovery industry, having worked as a medicinal chemist for Amgen, Sanofi and Icagen. She has worked in a wide range of fields, from antisense oligonucleotides, carbohydrate mimetics, and combinatorial chemistry to automated synthesis technology, design of compound collections and first and foremost inventing and progressing prospective small molecule drug candidates from concept to clinic for a wide range of disease areas, including oncology, autoimmune, inflammatory and central nervous system disorders. She resides in Boulder, Colorado, enjoying both the science and nature scene of the Front Range communities.

Wen-Hsuan Chang

As the head of AcuraStem’s Research Team, Wen-Hsuan Chang has worked with its founders to build the company from the ground up. Chang helped establish the core technology platform at AcuraStem, and now leads internal research projects and collaborations with external partners. Chang is responsible for therapeutic target identification, assay development for drug discovery, and platform expansion. She received a B.S. in Chemical Engineering from National Tsing Hua University in Taiwan. Following one year of investigation into neurotransmitter release biology at Fu-Jen Catholic University, she entered graduate school and received her Ph.D. in Chemical Engineering from the University of Southern California. During her graduate work at USC, Chang identified a novel mechanism through which Wnt signaling controls the development of the mammalian cortex. After her Ph.D., Chang performed postdoctoral work in Dr. Justin Ichida’s laboratory at USC where she identified key mechanisms by which the C9orf72 repeat expansion causes neurodegeneration in ALS and frontotemporal dementia. Chang also serves on the board of the Southern California Taiwanese Biotechnology Association and has published multiple peer-reviewed scientific research papers in journals for the fields of neuroscience, stem cell biology, and molecular biology.

Sarah Hong

Sarah graduated from the University of California, Los Angeles with a BS in Molecular, Cell, and Developmental Biology and a minor in biomedical research. At UCLA, she focused on characterizing a novel gene called Diet1 in the kidney proximal tubule epithelium. Sarah’s research interests in neuroscience were sparked when she participated in a summer research program in Peking University, China where she worked to inhibit pain engram cells in the anterior cingulate cortex via optogenetic stimulation.

Justin Ichida

Dr. Justin K. Ichida, PhD,  Scientific Advisory Board Chair and Co-Founder, is a highly-awarded scientist in the field of stem cell biology. Since 2013 he has held the position of Assistant Professor of Stem Cell and Regenerative Medicine at the University of Southern California’s Keck School of Medicine where he oversees research at the Ichida Lab and serves as Director of the Choi Family Therapeutic Screening facility. Dr. Ichida is a world renowned expert and inventor in the conversion of somatic cells directly into specific neural subtypes that recapitulate bona fide neurodegenerative disease processes in vitro. Ichida co-authored the groundbreaking research paper "Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons," published in Nature Medicine February 5, 2018. He was the principal investigator on the study. He is also a New York Stem Cell Foundation – Robertson Stem Cell Investigator and was recently named a Richard N. Merkin Scholar.

Emily Elizabeth Lee

Emily began her career at the Scripps Health Shiley Center for Orthopedic Research & Education in San Diego, California before moving on to work as a Neuroscience Drug Discovery Scientist for Ionis Pharmaceuticals. Along the way, she co-authored several important publications based on her work in the lab, including research featured in the peer-reviewed journals Cartilage and Nanomedicine. Emily graduated from the University of California, Santa Cruz with a BA in Biology.

Qing Liu

Dr. Qing Liu, PhD, Co-Founder, has directed research projects both in academia and industry and possesses over 15 years’ experience in scientific project management in a broad range of diseases and cellular models as well as technical expertise in high content screening. Dr. Liu has a long track record of fostering successful R&D collaborations. She has many years’ experience in motor neuron disease research. In her graduate thesis, Dr. Liu established that haplodeficiency of the Survival of Motor Neuron (SMN) protein causes Spinal Muscular Atrophy and later developed high content screens for ALS at Harvard Medical School. She is an expert at business development, licensing, and negotiations in the pharmaceutical area. At USC, within three short years, she has raised over $4M from individuals and foundations to support the mission of the institute.

Stacee Mendoca

Stacee began her research career at the Department of Microbiology, Immunology, and Molecular Genetics at UCLA in 2016. At UCLA, she was part of a team that discovered, isolated, and purified a novel bacteriophage, designed an experiment to determine bacteriophage kinetics and lifecycle, and identified a potential new gene function never seen in Propionibacterium acnes bacteriophages. Recently, Stacee joined AcuraStem after serving as a Research Associate at City of Hope’s Department of Molecular Imaging and Therapy in Duarte, California, where her work in viral encephalitis garnered her extensive experience in central nervous system inflammatory disorders and their biomarkers. She graduated from the University of California, Los Angeles with a BS in Microbiology, Immunology, & Molecular Genetics.


Scientific board of Advisors

Robert Bowser

Dr. Bowser is the Chief Scientific Officer, the John and Betty VanDenburgh Chair of Neuromuscular Disease as well as Professor and Chairman of the Department of Neurobiology at the Barrow Neurological Institute (BNI) and St. Joseph’s Hospital and Medical Center. He is also the Founder and President of Iron Horse Diagnostics, Inc. Dr. Bowser is a co-chair of the Northeast ALS Consortium (NEALS) BioRepository Committee, and Director of the Target ALS and ALS Association TDP-43-Focused Biomarker Initiative. He has led the establishment of  standardized protocols for the collection and processing of human cerebrospinal fluid, blood, and post-mortem tissue samples for biomarker studies in ALS, and performed large proteomic and metabolomics discovery and validation studies for ALS biomarkers.

Jack Dean

Dr. Jack Dean currently is the Founder and President of Drug Development Advisors, LLC, a consulting firm on drug safety, drug development, regulatory strategy, and immunotoxicology. Dr. Dean has a B.S. in microbiology and an M.S. in medical microbiology from California State University at Long Beach, and a Ph.D. from University of Arizona in molecular biology and minor in biochemistry from the Department of Micro and Molecular Biology in the College of Medicine. He holds a research professorship in the Department of Pharmacology and Toxicology at the College of Pharmacy, University of Arizona. He retired in January 2006 as President, U.S. Science and Medical Affairs (R&D), Sanofi-Aventis and as the Global Director of Preclinical Development for Sanofi-Aventis (Paris) after 18 years with Sanofi. During his tenure there, Dr. Dean was involved with the registration of eight NDAs for the U.S. and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin.

Over the course of his expansive career he worked as Director of the Department of Toxicology, Vice President, Drug Safety (worldwide), Research Center Director (Alnwick, UK) and Executive Vice President, Drug Development for Sterling Winthrop; head of the Department of Cellular and Molecular Toxicology, Chemical Industry Institute of Toxicology; head of the Immunotoxicology Section, National Institute of Environmental Health Services, National Institutes of Health; and head of the Department of Immunology, Litton Bionetics.

Daniel Geschwind

Dr. Daniel Geschwind is the Gordon and Virginia MacDonald Distinguished Chair in Human Genetics and is a professor of Neurology and Psychiatry at the David Geffen School of Medicine at UCLA. In his capacity as Senior Associate Dean and Associate Vice Chancellor of Precision Health, he leads the Institute for Precision Health at UCLA. His laboratory has pioneered the application of systems biology methods in neurologic and psychiatric disease, with a focus on autism spectrum disorders (ASD) and neurodegenerative conditions. Dr. Geschwind has published over 400 papers and currently serves on the editorial boards of Cell and Neuron and Science, alongside his responsibilities as a Member of the American Association of Physicians and the National Academy of Medicine.

Michael Sheha

Michael Sheha is the co-founder and CEO of ten9.com, a company whose purpose is to “organize life’s most meaningful experiences”. He serves on USC’s Viterbi School of Engineering Advisory Board and USC’s Board of Governors representing the Viterbi School of Engineering. Previously he co-founded Networks In Motion (NIM) in 2000, a wireless navigation company, which powered location-based services and search for leading mobile partners around the world including Verizon Wireless (VZ Navigator), AAA, AT&T, Sprint, Telus, Alltel, and more. NIM's platform was one of the most widely used paid wireless navigation services in North America at the time of acquisition in 2009 by TCS. The company was headquartered in Orange County, Calif. with additional offices throughout the EU, China, and Silicon Valley. Prior to co-founding NIM, Sheha worked at the Caltech-NASA Jet Propulsion Laboratory’s wireless communication systems and research section responsible for the design and development of digital and radio frequency communication systems, military GPS tracking systems, and the R&D in communication link and propagation studies. Michael has published over 56+ patents throughout his career.

Douglas A. Treco

Douglas Treco is the Chief Executive Officer and a Director of Ra Pharmaceuticals, a public biotechnology company developing treatments for complement-mediated disorders, which he founded in 2008.  He received a PhD degree in Biochemistry and Molecular Biology from SUNY at Stony Brook and performed post-doctoral studies at the Salk Institute and Massachusetts General Hospital. In 1988 Dr. Treco co-founded Transkaryotic Therapies, Inc. (TKT, acquired in 2005 by Shire plc), a multi-platform biopharmaceutical company developing protein and gene therapy products. As Senior Vice President of Research and Development, he established and directed TKT’s gene activation and protein production efforts, which led to the approval of the biopharmaceutical products Dynepo™, Replagal®, Elaprase®, and Vpriv™. From 2004 to 2008, Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at MGH and a Lecturer in Genetics at Harvard Medical School, and from 2008 to 2014, he was an Entrepreneur-in-Residence with Morgenthaler Ventures. He has authored numerous peer-reviewed publications and holds over 40 US and European patents in the areas of protein and peptide production, gene mapping, and gene therapy.